Sars-CoV-2 Infection
401
11
29
220
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
58 trials with published results (14%)
Research Maturity
220 completed trials (55% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.0%
28 terminated out of 401 trials
88.7%
+2.2% vs benchmark
15%
59 trials in Phase 3/4
26%
58 of 220 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 220 completed trials
Clinical Trials (401)
Efficacy and Safety of NVX-CoV2705
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine
T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
PET/CT Imaging in COVID-19 Patients
Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva
COVID-19 on Placental Gene Expression and Pathology
Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test
Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)